ACTU (Actuate Therapeutics) Current Accrued Expense: $2.64 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ACTU Actuate Therapeutics Inc ACTU
14 GF Score
Price $1.19
View Full Analysis

What is Actuate Therapeutics Current Accrued Expense?

Actuate Therapeutics ACTU -7.09% 14 Current Accrued Expense is $2.64 Mil as of Mar. 2026. GuruFocus rates ACTU with a GF Score™ of 14/100.

Actuate Therapeutics's Current Accrued Expense for the quarter that ended in Mar. 2026 was $2.64 Mil.

Actuate Therapeutics's quarterly Current Accrued Expense declined from Sep. 2025 ($4.28 Mil) to Dec. 2025 ($3.60 Mil) and declined from Dec. 2025 ($3.60 Mil) to Mar. 2026 ($2.64 Mil).

Actuate Therapeutics's annual Current Accrued Expense increased from Dec. 2023 ($3.22 Mil) to Dec. 2024 ($5.99 Mil) but then declined from Dec. 2024 ($5.99 Mil) to Dec. 2025 ($3.60 Mil).

Actuate Therapeutics Current Accrued Expense Related Terms

Actuate Therapeutics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Actuate Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actuate Therapeutics Current Accrued Expense Chart

Actuate Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
2.08 3.22 5.99 3.60

Actuate Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.27 4.64 4.28 3.60 2.64
ACTU
14GF Score
Actuate Therapeutics Inc ACTU
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Actuate Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $2.64 Mil mean?
Actuate Therapeutics (ACTU) has a Current Accrued Expense of $2.64 Mil as of Mar. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Actuate Therapeutics and its competitors.
Is Actuate Therapeutics' Current Accrued Expense too high?
Actuate Therapeutics' current Current Accrued Expense is $2.64 Mil. Overall, Actuate Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Actuate Therapeutics' Current Accrued Expense compare to RNXT and ESLA?
Actuate Therapeutics' Current Accrued Expense of $2.64 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Actuate Therapeutics and its competitors. Actuate Therapeutics's current Current Accrued Expense is $2.64 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actuate Therapeutics stock overvalued right now?
Actuate Therapeutics (ACTU) has a current Current Accrued Expense of $2.64 Mil. The current Current Accrued Expense is $2.64 Mil. Actuate Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Actuate Therapeutics (ACTU), the current Current Accrued Expense is $2.64 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actuate Therapeutics Business Description

Address 1751 River Run, Suite 400, Fort Worth, TX, USA, 76107
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
14GF Score

Get the complete analysis for ACTU

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.19
Price